China Sorafenib Market Investigation Report 2015-2019
DUBLIN, Aug. 17, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/hn62gs/investigation) has announced the addition of the "Investigation Report on China's Sorafenib Market, 2010-2019" report to their offering.
The incidence of liver cancer and kidney cancer in China grew gradually over time. According to the Guidelines for the Kidney Cancer Diagnosis and Treatment in China (the 2013 version), kidney cancer accounts for 2%-3% of adult malignant tumors in China and reports an obvious rise in incidence in recent years in China.
Kidney cancer has surpassed bladder cancer to become the first in death related with urological tumors with its incidence growing at an average rate of 6.5% during the past two decades. According to the World Cancer Report 2014, China ranked first in the new cases of liver cancer and its death toll.
Currently, liver cancer, with 0.257 in one million suffering from it, has become the third malignant tumor after stomach cancer and lung cancer in terms of mortality. As a novel small molecular multi-targeted inhibitor of tyrosine kinase, sorafenib is approved by the FDA to treat unresectable advanced renal cell carcinoma and unresectable or metastasized primary hepatocellular carcinoma. Co-developed by Bayer and Onyx Pharmaceuticals, sorafenib got imported drug license in 2006 and was approved by China Food and Drug Administration to enter the market for the treatment of liver cancer in 2008.
According to this survey on 20 sample hospitals in key regions in China, sales value of sorafenib was CNY 147 million in 2013 and CNY 165 million in 2014, increasing 12.24% year on year.
With the degradation of environmental pollution and changes in lifestyle, the incidence of liver cancer keeps rising. Hence the vast demand for sorafenib in China. Currently, sorafenib in the Chinese market all come from Bayer AG i.e. Bayer enjoys a market share of 100%.
Key Topics Covered:
1 Related Concepts of Sorafenib
2 Market Profile of Sorafenib in China
3 Survey on Sales Status of Sorafenib in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Sorafenib in China, 2010-2014
5 Survey on Dosage Forms of Sorafenib in China, 2010-2014
6 Reference Price of Sorafenib in Chinese Hospitals in 2014
7 Major Manufacturers of Sorafenib in Chinese Market, 2010-2014
8 Outlook of Sorafenib Market in China, 2015-2019
For more information visit http://www.researchandmarkets.com/research/hn62gs/investigation
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article